BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032

“BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032” report provides comprehensive insights about BRII-835 + BRII-179 for chronic hepatitis B in the seven major markets and China. A detailed picture of the BRII-835 + BRII-179 for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019 -2032 is provided in this report along with a detailed description of the BRII-835 + BRII-179 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BRII-835 + BRII-179 market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary

BRII-836 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that can stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index.

Also, BRII-179 (VBI-2601) is a novel recombinant, protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens and is designed to induce enhanced B-cell and T-cell immunity. Brii Bio licensed BRII-179 (VBI-2601) from VBI Vaccines in December 2018, providing Brii Bio with commercial rights to BRII-179 (VBI-2601) in the licensed territories of Mainland China, China Hong Kong, Macau, and Taiwan.

Both agents have demonstrated proof of mechanism in HBV patients; a combination might be a potential functional cure. It encompasses dual mechanisms of action, removing immunosuppressive viral antigens by siRNA gene silencing followed by stimulating and restoring the host HBV-specific immunity with an immunotherapeutic vaccine.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the BRII-835 + BRII-179 description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on BRII-835 + BRII-179 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BRII-835 + BRII-179 research and development activities in chronic hepatitis B across the United States, Europe, Japan, and China.
• The report also covers the patents information with expiry timeline around BRII-835 + BRII-179.
• The report contains forecasted sales of BRII-835 + BRII-179 for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for BRII-835 + BRII-179 in chronic hepatitis B.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BRII-835 + BRII-179 Analytical Perspective

In-depth BRII-835 + BRII-179 Market Assessment

This report provides a detailed market assessment of BRII-835 + BRII-179 for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China. This segment of the report provides forecasted sales data from 2027 to 2032.

BRII-835 + BRII-179 Clinical Assessment

The report provides the clinical trials information of BRII-835 + BRII-179 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BRII-835 + BRII-179 dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to BRII-835 + BRII-179 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BRII-835 + BRII-179 in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of BRII-835 + BRII-179 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BRII-835 + BRII-179 in chronic hepatitis B.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of BRII-835 + BRII-179?
• What is the clinical trial status of the study related to BRII-835 + BRII-179 in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BRII-835 + BRII-179 development?
• What are the key designations that have been granted to BRII-835 + BRII-179 for chronic hepatitis B?
• What is the forecasted market scenario of BRII-835 + BRII-179 for chronic hepatitis B?
• What are the forecasted sales of BRII-835 + BRII-179 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China?
• What are the other emerging products available and how are these giving competition to BRII-835 + BRII-179 for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

This product will be delivered within 2 business days.